Matthew Venezia
Stock Analyst at Alliance Global Partners
(0.53)
# 4,309
Out of 5,010 analysts
15
Total ratings
20%
Success rate
-12.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Venezia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Initiated Coverage: Buy | $32 | $21.89 | +46.19% | 1 | Sep 21, 2026 | |
| AKTX Akari Therapeutics, | Reiterated: Buy | $20 | $9.55 | +104.19% | 1 | Sep 16, 2026 | |
| MDCX Medicus Pharma | Reiterated: Buy | $1 | $0.1566 | +538.57% | 1 | Sep 14, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Hold | n/a | $8.57 | - | 8 | Jul 30, 2026 | |
| NTHI NeOnc Technologies Holdings | Initiated Coverage: Buy | $13 | $3.30 | +293.94% | 1 | May 19, 2026 | |
| PLUR Pluri | Initiated Coverage: Buy | $12 | $1.01 | n/a | 1 | Jun 2, 2025 | |
| CBUS Cibus | Reiterated: Buy | $24 | $1.55 | n/a | 2 | May 9, 2025 |
Immunome
Sep 21, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $21.89
Upside: +46.19%
Akari Therapeutics,
Sep 16, 2026
Reiterated: Buy
Price Target: $20
Current: $9.55
Upside: +104.19%
Medicus Pharma
Sep 14, 2026
Reiterated: Buy
Price Target: $1
Current: $0.1566
Upside: +538.57%
Capricor Therapeutics
Jul 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.57
Upside: -
NeOnc Technologies Holdings
May 19, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $3.30
Upside: +293.94%
Pluri
Jun 2, 2025
Initiated Coverage: Buy
Price Target: $12
Current: $1.01
Upside: n/a
Cibus
May 9, 2025
Reiterated: Buy
Price Target: $24
Current: $1.55
Upside: n/a